Anzeige
Mehr »
Login
Mittwoch, 18.09.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Während Gold ein neues Allzeithoch erreicht und Zentralbanken Gold horten, könnte diese eine Aktie um 1.000 % steigen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J5GZ | ISIN: SE0004840718 | Ticker-Symbol: 3XV
Frankfurt
17.09.24
08:01 Uhr
44,700 Euro
+0,400
+0,90 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
XVIVO PERFUSION AB Chart 1 Jahr
5-Tage-Chart
XVIVO PERFUSION AB 5-Tage-Chart
ACCESSWIRE
346 Leser
Artikel bewerten:
(2)

XVIVO Perfusion AB: Extended Perfusion Time of Livers Can Streamline Planning and Logistics - Enabling More Liver Transplants to be Performed During Daytime

GOTHENBURG, SE / ACCESSWIRE / January 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) In a recently published [1] clinical trial conducted by the UMCG in Groningen, the Netherlands, XVIVO's Liver Assist has demonstrated its potential to reshape liver transplant logistics. The trial showed that donor livers could be transplanted with consistently good outcomes after up to 20 hours of preservation using DHOPE. This finding provides transplant clinics with the opportunity, for the first time, to plan the timing of a transplant and avoid night time surgery. By extending perfusion times, UMCG in 2023 was able to perform the majority of all liver transplants during daytime rather than nighttime.

Liver transplant logistics have long been constrained by the limited time organs can be kept viable outside the donor's body and transplant procedures most often occur during nighttime and under time pressure. This clinical trial marks a turning point by demonstrating the feasibility of prolonging the preservation of donor livers with DHOPE (Dual Hypothermic Oxygenated Perfusion) for up to 20 hours providing flexibility in transplant logistics. This could facilitate successful daytime transplantation, which, for example, can lead to more liver transplants being scheduled during daytime.

The investigator-initiated, prospective, dual-arm clinical trial at UMCG aimed to assess the safety and feasibility of prolonged DHOPE compared to the standard DHOPE method, which typically lasts 1-2 hours. The study results indicate no significant differences in serious adverse events, liver graft-related complications, or patient and graft survival between the two groups.

"Operations no longer have to be carried out immediately after a donor organ becomes available, eliminating the need for nighttime procedures. This not only reduces the demand for night shift teams but also contributes to the sustainable employability of all those directly involved. I am proud to say that in 2023, at UMCG, we performed a majority of transplants during daytime. Furthermore, the trial has lowered the threshold for combined heart-liver or lung-liver transplantation. The ability to safely store the liver for an extended period allows heart or lung transplants to be prioritized, followed by a liver transplant with less time pressure. Additionally, after the trial, we discovered that liver transplants were, on average, almost two hours shorter than those performed at night. This suggests that fitter teams during the day contribute to streamlined procedures", says Professor Vincent de Meijer, Head of liver transplantation and chair UMCG transplantation center, UMCG in Groningen, the Netherlands.

"When developing technologies for organ transplantation, our primary and most important goal is to achieve safe and successful transplantations for the patients. Nonetheless, the ability to support transplant clinics in streamlining their planning and logistics challenges is crucial. It is very pleasing that our Liver Assist's flexibility has been demonstrated to support improved processes without compromising patient safety", says Christoffer Rosenblad, CEO XVIVO.

January 24, 2024
Gothenburg
Christoffer Rosenblad, CEO
XVIVO Perfusion AB (publ)

[1] https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00588-6/fulltext

For further information, please contact:

Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.

Attachments

Extended perfusion time of livers can streamline planning and logistics - enabling more liver transplants to be performed during daytime

SOURCE: XVIVO Perfusion AB



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Besser als NVIDIA! 3 KI- Favoriten mit riesigem Potenzial

Erleben Sie die KI-Revolution und sichern Sie sich gigantische Gewinne!

Nutzen Sie die einmalige Gelegenheit, die Ihnen die Künstliche Intelligenz bietet! Unser exklusiver Aktienreport enthüllt drei unglaublich aussichtsreiche KI-Aktien, die von der bahnbrechenden Entwicklung in diesem Sektor massiv profitieren können.

Warum sollten Sie dabei sein?

Weil eine Investition in KI-Unternehmen nicht nur Stabilität bringt, sondern auch das Potenzial hat, Ihr Depot explosionsartig wachsen zu lassen. Die letzten Jahre haben bewiesen: Wer auf KI setzt, kann außergewöhnliche Gewinne einfahren. Jetzt, nach einer kurzen Konsolidierungsphase, öffnen sich wieder sensationelle Einstiegsmöglichkeiten.

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche KI-Aktien das größte Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen die besten Investments im KI-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.